

 **BLENREP**
belantamab
mafodotin-blmf
for injection 70 mg

I want to be a

come back kid



**3x LONGER
REMISSION
WITH THE BLENREP
COMBINATION VS
THE DARATUMUMAB COMBINATION*†**

Christopher

BLENREP may help power a comeback to remission if his multiple myeloma returns

Not an actual patient.

*Remission here refers to median progression-free survival, the length of time after the start of treatment in which a person is alive and their cancer does not get worse.

†In a clinical study named DREAMM-7, people taking the BLENREP + bortezomib + dexamethasone combination stayed in remission for 31 months, compared to 10 months with the daratumumab + bortezomib + dexamethasone combination.

Individual results may vary.

What is BLENREP?

BLENREP is a prescription medicine used in combination with the medicines bortezomib and dexamethasone to treat adults with multiple myeloma who:

- have received at least 2 prior treatments, including a proteasome inhibitor and an immunomodulatory agent, and
- their cancer has come back or did not respond to prior treatment.

It is not known if BLENREP is safe and effective in children.

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.

Important Safety Information

What is the most important information I should know about BLENREP?

BLENREP can cause serious side effects, including:

- **Eye problems.** Eye problems are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
 - decreased vision
 - blurred vision
 - dry eyes
 - sensitivity to light
 - feeling like something is in your eyes
 - eye irritation
 - eye pain

Reimagine what tomorrow can bring with the BLENREP combination

How patients responded to BLENREP 4

Eye changes with BLENREP—what you need to know 6

How eye changes are monitored and managed by your care team 8

Starting BLENREP—what to expect 10

How BLENREP works 11

Support programs and resources for you 12



Consider this brochure your guide—designed to help you feel more informed and empowered every step of the way.



Hilary
BLENREP may help power
a comeback to remission if her
multiple myeloma returns
Not an actual patient.

Important Safety Information for BLENREP (cont'd)

Ulcers on the surface of the eye (corneal ulcers), including with infection, may also happen during treatment with BLENREP.

Tell your healthcare provider right away if you notice any new or worsening eye symptoms or vision changes during treatment with BLENREP.


The BLENREP combination delivered 3x longer time in remission

DREAMM-7 Study

The DREAMM-7 study was a global clinical trial. It compared treatment with BLENREP + bortezomib + dexamethasone to a common treatment combination with daratumumab.

The efficacy of BLENREP was established in a clinical study in adults with multiple myeloma who had received 2 or more prior treatments, including a proteasome inhibitor and an immunomodulatory agent, and experienced disease progression. Patients were split into 2 groups: 108 people were given **BLENREP + bortezomib + dexamethasone**, and 109 people were given **daratumumab + bortezomib + dexamethasone**.

People taking the BLENREP combination stayed in remission for 31 months, compared to 10 months with the daratumumab combination



3X LONGER REMISSION: DIFFERENCE OF 21 MONTHS

Median is the middle number in a set of data, where half of the people had longer results than this middle number and half had shorter.

Remission here refers to median progression-free survival, the length of time after the start of treatment in which a person is alive and their cancer does not get worse.


Individual results may vary.

Important Safety Information for BLENREP (cont'd)

Your healthcare provider will refer you to an eye care specialist (such as an ophthalmologist or optometrist) to check your eyes before you start treatment, before you receive each dose of BLENREP, and as needed for any new or worsening eye problems. **It is important that you:**


- Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.



More people on the BLENREP combination lived longer

Overall survival



Median is the middle number in a set of data. Reaching the median means that half the people lived longer than this middle number, and half did not.

Individual results may vary.

Overall survival refers to the length of time people were still alive from when they were randomly assigned to a treatment group.

*Median overall survival was not yet reached means that more than half the people were still alive at the time data were collected.



Susan
BLENREP may help power a comeback to remission if her multiple myeloma returns


Not an actual patient.

Important Safety Information for BLENREP (cont'd)

- Use preservative-free artificial tears at least 4 times per day starting with your first infusion and continuing until the end of treatment with BLENREP
- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye care specialist

Most people responded to the BLENREP combination

Overall response rate†



†Due to rounding, exact totals are 1% higher (83% and 58%).

Individual results may vary.

Overall response rate: the percentage of people who respond to a treatment with a partial response or better

Stringent complete response: the highest response when cancer cells cannot be found in the bone marrow‡

Complete response: when blood and urine tests show no signs of cancer cells‡

Very good partial response: when at least 90% of cancer cells have left the blood and urine

Partial response: when cancer cells decrease in the blood and urine by at least 50%

‡This does not mean the disease has been cured.

Important Safety Information for BLENREP (cont'd)

- Use caution when driving or operating machinery because BLENREP may cause changes to your vision

Please see additional Important Safety Information throughout.
Click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

Eye and vision changes were common with the BLENREP combination and could be severe, but improvement of these changes was possible

89% of those treated with the BLENREP combination had a reduction in vision in at least 1 eye in the BLENREP clinical study, meaning their vision was less sharp, even with corrective lenses

- Changes in vision were measured by the Best-Corrected Visual Acuity (BCVA) test
- Nearly one-third of patients did not experience a change in vision up to 20/50 (see the slight blurring pictured below)

For patients who did experience a vision change in at least 1 eye



Images are for illustrative purposes only. Vision will differ for each individual. Images created with an Eye Care Professional.

Of people with reduced vision in at least 1 eye, some experienced resolution of their last vision reduction to baseline or better




Important Safety Information for BLENREP (cont'd)

Because of the risk of eye problems, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS). Your healthcare provider will give you the BLENREP REMS Patient Guide, which describes the risk of eye problems, and will explain the REMS program to you.

BLENREP can affect the cornea—the outermost layer of the eye


Changes occur in the cornea, the clear outer layer at the front of your eye—this is at the surface of the eye, not deep inside.



Important Safety Information for BLENREP (cont'd)

To receive BLENREP, you must enroll in the REMS program and receive eye exams during treatment. See “What are the possible side effects of BLENREP?” for more information about side effects.

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.



Your care team works together to support you so you can stay focused on your treatment journey

Regular eye exams are needed before each dose of BLENREP


Your eye doctor, either an **optometrist or ophthalmologist**, will perform 2 eye checks that are similar to a routine eye exam. These are done before starting BLENREP, before each dose, and as needed for new or worsening symptoms.



Slit Lamp Exam



Snellen Eye Chart Exam



These exams do not typically require dilation (widening of the pupil). But your doctor may perform a full examination.

Important steps you can take to help protect your eyes

- Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam
- Use preservative-free artificial tears at least 4 times per day starting with your first infusion and continuing until the end of treatment with BLENREP
 - You may be eligible for eye drops at no cost to you through the BLENREP Eye Drop Program. [Click here](#) for more information
- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye care specialist
- Use caution when driving or operating machinery because BLENREP may cause changes to your vision

Talk to your doctor about side effects

Important Safety Information for BLENREP (cont'd)

What are the possible side effects of BLENREP?

BLENREP can cause serious side effects, including:

- See “Eye Problems” in “What is the most important information I should know about BLENREP?”
- **Decrease in platelets (thrombocytopenia)** is common with BLENREP and can also be severe. Platelets are a type of blood cell that help your blood to clot. Your healthcare provider will check your blood cell counts before you start treatment with BLENREP and during treatment as needed. Tell your healthcare provider if you get any bleeding or bruising during treatment with BLENREP

Your oncologist may make changes to your dose to help manage your eye and vision changes

Based on eye exam results from your eye doctor, your oncologist may choose to:



CONTINUE your dose and schedule of BLENREP



REDUCE your dose of BLENREP



PAUSE your dose of BLENREP




STOP your BLENREP treatment

Important Safety Information for BLENREP (cont'd)

The most common side effects of BLENREP when given with bortezomib and dexamethasone include:

- See “Eye problems” in “What is the most important information I should know about BLENREP?”
- upper respiratory tract infection
- liver problems
- diarrhea
- tiredness
- pneumonia
- cataract
- COVID-19

Please see additional Important Safety Information throughout. Click to see the full **Prescribing Information**, including **Boxed Warning** and **Medication Guide** for BLENREP.



Getting started with BLENREP

BLENREP infusion



BLENREP will be given to you at a certified BLENREP Risk Evaluation and Mitigation Strategy (REMS) outpatient site



BLENREP is given as an intravenous (IV) infusion usually every 3 weeks, in combination with bortezomib and dexamethasone—your healthcare provider will decide how many treatments you will need

If you miss any appointments, call your healthcare provider as soon as possible to reschedule.

BLENREP is a treatment designed to fit into your life



Infusion can be as short as 30 minutes



No hospitalization is needed to start BLENREP



BLENREP may be given by your current care team in your community if they participate in REMS



No pre-medications are needed in order to receive BLENREP

Talk to your doctor about where you can start treatment with BLENREP

Henry


BLENREP may help power a comeback to remission if his multiple myeloma returns

Not an actual patient.


BLENREP works in different ways—targeting myeloma cells from the inside out

BLENREP attacks multiple myeloma in multiple ways


No other treatment works like BLENREP—as the only B-cell maturation antigen (BCMA)-targeted antibody–drug conjugate (ADC), it takes on myeloma cells in multiple ways.



BLENREP attaches to BCMA, which is a protein on the surface of myeloma cells



An anticancer medicine goes inside the myeloma cells, directly destroying them from the inside



BLENREP also engages the immune system to fight and destroy myeloma cells from the outside

BCMA is found at higher levels on myeloma cells. BLENREP can affect normal cells.

Important Safety Information for BLENREP (cont'd)

The most common severe abnormal blood test results during treatment with BLENREP include decreases in platelets, white blood cells, and hemoglobin, and increases in certain liver enzymes.

Tell your healthcare provider right away if you get new or worsening unexplained signs or symptoms of lung problems, including shortness of breath, chest pain, or cough.

Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with BLENREP if you get serious side effects.

BLENREP may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of BLENREP.


Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Important Safety Information for BLENREP (cont'd)

Before receiving BLENREP, tell your healthcare provider about all of your medical conditions, including if you:

- have or had vision or eye problems
- have or had bleeding problems
- are pregnant or plan to become pregnant. BLENREP can harm your unborn baby

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.



The Together with BLENREP program is support made just for you

Here's what to expect from Together with BLENREP

It's more than a program—it's our promise to understand your needs, listen to what's important to you, and create meaningful connections along the way.

Once your doctor has prescribed BLENREP, we will help you to understand the medication coverage process, investigate affordable options, and guide you through moments that matter in your care.



Coverage Support*

Once you sign up for Together with BLENREP, your dedicated Nurse Navigator[†] will have your insurance coverage checked and help you understand your benefits. The information provided by Together with BLENREP is not a guarantee of coverage or payment

- Coverage verification for eye exams, infusions, and BLENREP prescriptions



Cost Support‡

Along with your existing insurance, your dedicated Nurse Navigator can give you information on additional programs that may help you pay for BLENREP

- There are options for copay assistance for eye exams and eye drops (subject to eligibility)



Patient Support

Once you sign up for Together with BLENREP, your dedicated Nurse Navigator can help you, your oncologist, your Eye Care Professional, and their office staff work together during your treatment journey with BLENREP

*There may be current coverage restrictions or requirements that may apply; be sure to contact your plan for more information. The information provided by Together with BLENREP is not a guarantee of coverage.

†The Nurse Navigator does not provide medical advice and is not a part of your doctor's care team. Please ask your doctor any questions that you might have about your disease and treatment with BLENREP.

‡Together with BLENREP cannot guarantee that you will be eligible for assistance from a foundation, as each foundation has their own rules on eligibility which are subject to change.

Navigating access together: personalized support for coverage, costs, and your care journey



You can enroll in Together with BLENREP in 2 ways:

Online enrollment

You can start the enrollment process directly online at the **Together with BLENREP website**. You will need to fill out patient information, sign the form digitally, and submit it.

OR

Fax/Paper enrollment

You can **download** and print this form, complete it with the help of your oncologist, and have the office submit it.

To learn more about Together with BLENREP and enroll, [click here](#)

Please see Important Safety Information throughout. Click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

Important Safety Information for BLENREP

What is the most important information I should know about BLENREP?

BLENREP can cause serious side effects, including:

- **Eye problems.** Eye problems are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
 - decreased vision
 - dry eyes
 - feeling like something is in your eyes
 - eye irritation
 - blurred vision
 - sensitivity to light
 - eye pain

Ulcers on the surface of the eye (corneal ulcers), including with infection, may also happen during treatment with BLENREP.

Tell your healthcare provider right away if you notice any new or worsening eye symptoms or vision changes during treatment with BLENREP.

Your healthcare provider will refer you to an eye care specialist (such as an ophthalmologist or optometrist) to check your eyes before you start treatment, before you receive each dose of BLENREP, and as needed for any new or worsening eye problems. **It is important that you:**

- Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam
- Use preservative-free artificial tears at least 4 times per day starting with your first infusion and continuing until the end of treatment with BLENREP
- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye care specialist
- Use caution when driving or operating machinery because BLENREP may cause changes to your vision

Because of the risk of eye problems, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS). Your healthcare provider will give you the BLENREP REMS Patient Guide, which describes the risk of eye problems, and will explain the REMS program to you. To receive BLENREP, you must enroll in the REMS program and receive eye exams during treatment. See **“What are the possible side effects of BLENREP?”** for more information about side effects.

What are the possible side effects of BLENREP?

BLENREP can cause serious side effects, including:

- See **“Eye Problems”** in **“What is the most important information I should know about BLENREP?”**
- **Decrease in platelets (thrombocytopenia)** is common with BLENREP and can also be severe. Platelets are a type of blood cell that help your blood to clot. Your healthcare provider will check your blood cell counts before you start treatment with BLENREP and during treatment as needed. Tell your healthcare provider if you get any bleeding or bruising during treatment with BLENREP

The most common side effects of BLENREP when given with bortezomib and dexamethasone include:

- See **“Eye problems”** in **“What is the most important information I should know about BLENREP?”**
- upper respiratory tract infection
- liver problems
- diarrhea
- tiredness
- pneumonia
- cataract
- COVID-19

The most common severe abnormal blood test results during treatment with BLENREP include decreases in platelets, white blood cells, and hemoglobin, and increases in certain liver enzymes.

Tell your healthcare provider right away if you get new or worsening unexplained signs or symptoms of lung problems, including shortness of breath, chest pain, or cough.

Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with BLENREP if you get serious side effects.

BLENREP may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of BLENREP.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before receiving BLENREP, tell your healthcare provider about all of your medical conditions, including if you:

- have or had vision or eye problems
- have or had bleeding problems
- are pregnant or plan to become pregnant. BLENREP can harm your unborn baby

Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start treatment with BLENREP
- Use effective birth control during treatment with BLENREP and for 4 months after the last dose. Talk to your healthcare provider about birth control methods you can use during this time
- Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with BLENREP

Males with female partners who are able to become pregnant:

- Use effective birth control during treatment with BLENREP and for 6 months after the last dose
- are breastfeeding or plan to breastfeed. It is not known if BLENREP passes into your breast milk. Do not breastfeed during treatment with BLENREP and for 3 months after the last dose

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.

Please click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

I want to be a

come back kid

REIMAGINE WHAT TOMORROW CAN BRING WITH THE BLENREP COMBINATION

Talk to your doctor to see if BLENREP is right for you.
See inside for more information.

Maria

BLENREP may help power a comeback to remission if her multiple myeloma returns

Not an actual patient.

TO LEARN MORE,
VISIT [BLENREP.COM](https://www.blenrep.com)

What is BLENREP?

BLENREP is a prescription medicine used in combination with the medicines bortezomib and dexamethasone to treat adults with multiple myeloma who:

- have received at least 2 prior treatments, including a proteasome inhibitor and an immunomodulatory agent, and
- their cancer has come back or did not respond to prior treatment.

It is not known if BLENREP is safe and effective in children.

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.

Important Safety Information

What is the most important information I should know about BLENREP?

BLENREP can cause serious side effects, including:

- **Eye problems.** Eye problems are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
 - decreased vision
 - blurred vision
 - dry eyes
 - sensitivity to light
 - feeling like something is in your eyes
 - eye irritation
 - eye pain

Trademarks are owned by or licensed to the GSK group of companies.

GSK

©2026 GSK or licensor.
PMUS-BLMBROC260006 June 2026
Produced in USA.

File Name: Patient Education Brochure

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg